目的 探讨疏风解毒胶囊对D-氨基半乳糖/脂多糖致大鼠急性肝损伤的保护作用及其机制。方法 SD大鼠80只,随机分为对照组、模型组、疏风解毒胶囊组、地塞米松组,每组20只。对照组大鼠ip生理盐水0.5 mL,其他各组ip D-氨基半乳糖(D-GalN)700 mg/kg和脂多糖(LPS)10 μg/kg制备急性肝损伤模型。地塞米松组每天ip地塞米松5 mg/kg、疏风解毒胶囊组每天ig疏风解毒胶囊100 mg/kg,每天1次,连续给药7 d。取各组大鼠肝组织进行HE染色观察病理学变化;酶联免疫吸附法(ELISA)检测血清相关指标:丙氨酸氨基转移酶(ALT)及天冬氨酸氨基转氨酶(AST)、白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)、鸟氨酸氨基甲酰转移酶(OCT)、高迁移率族蛋白B-1(HMGB-1)、谷胱甘肽转移酶(GST)水平。结果 与模型组比较,疏风解毒胶囊组大鼠肝组织的病变程度较轻,大鼠血清ALT、AST、IL-1β、TNF-α、OCT、HMGB-1及GST水平明显下降(P < 0.05),疏风解毒胶囊组与地塞米松组比较,各项指标差异不显著(P > 0.05)。结论 疏风解毒胶囊可通过降低IL-1β及TNF-α水平抑制D-GalN/LPS诱导大鼠急性肝脏炎症反应,起到减轻D-GalN/LPS导致的急性肝损伤作用。

Objective To study the protective effects of Shufeng Jiedu Capsule on SD rats with acute liver injury induced by D- galactosamine/lipopolysaccharide (D-GalN/LPS). Methods Eighty SD rats with average 250 g weight were randomly divided into four groups: the saline control group, LPS-induced model group, Shufeng Jiedu Capsule treatment group, and dexamethasone treatment group with 20 in each group. The rats in the saline group were ip injected with 0.5 mL of saline, other three groups were ip injected with D-GalN 700 mg/kg and LPS 10 μg/kg in order to induce the model of acute liver injury, The rats in dexamethasone treatment group were ip injected with dexamethasone 5 mg/kg, the rats in Shufeng Jiedu Capsule treatment group were ig fed a daily dose 100 mg/kg of Shufeng Jiedu Capsule. At day 1, 3, 5, and 7, five rats from each group were killed and their liver tissues were taken for HE staining to observe pathological manifestations; Enzyme-linked immunosorbent assay (Elisa) was taken for the following tests: the levels of alanine transaminase (ALT) and aspartate aminotransferase (AST), interleukin-1β (IL-1β), tumor necrosis factor alpha (TNF-α), Ornithine carbamoyltransferase (OCT), high-mobility group protein (HMGB-1), and glutathione s-transferase (GST) were determined. Results Shufeng Jiedu Capsule could significantly alleviate the acute liver injury induced by D-GalN/LPS. Liver tissue of Shufeng Jiedu Capsule treatment group, compared to D-GaIN/LPS-induced model group, had lesser extent lesions. The levels of ALT and AST, IL-1β, TNF-α, OCT, HMGB-1, and GST were significantly lower than those of D-GalN/LPS model group (P < 0.05). Comparing the Shufeng Jiedu Capsule treatment group with dexamethasone treatment group, there was no significant difference in ALT and AST, IL-1β, TNF-α, OCT, HMGB-1, and GST between the two groups (P > 0.05). Conclusion Shufeng Jiedu Capsule could inhibit the liver cell expression of IL-1β and TNF-α so as to reduce the acute liver injury induced by D-GalN/LPS.